GLENMARK PHARMACEUTICALS (532296) — Latest Corporate Announcements
₹2,264.1
₹-18.90 (-0.83%)
Market Cap
₹63,898.49 Cr
P/E Ratio
35.39
52W Range
₹1792.6 – ₹2537.6
Corporate Actions & Regulatory Filings
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
To consider and approve the financial results for the period ended Jun 30, 2026
To consider and approve the financial results for the period ended March 31, 2026 and dividend
To consider and approve the financial results for the period ended December 31, 2025
To consider and approve the financial results for the period ended September 30, 2025
To consider and approve the financial results for the period ended June 30, 2025
To consider and approve the financial results for the period ended March 31, 2025 and dividend
To consider and approve the financial results for the period ended December 31, 2024
To consider and approve the financial results for the period ended September 30, 2024
To consider and approve the financial results for the period ended Jun 30, 2024
To consider and approve the financial results for the period ended March 31, 2024 and dividend
To consider and approve the financial results for the period ended December 31, 2023
To consider and approve the financial results for the period ended September 30, 2023
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Jun-2026 (Q1 FY27) | 31-Jul-2026 | Declared | To consider and approve the financial results for the period ended Jun 30, 2026 |
| Year Ended 31-Mar-2026 (Q4 FY26) | 29-May-2026 | Declared | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 30-Jan-2026 | Declared | To consider and approve the financial results for the period ended December 31, 2025 |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 14-Nov-2025 | Declared | To consider and approve the financial results for the period ended September 30, 2025 |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 14-Aug-2025 | Declared | To consider and approve the financial results for the period ended June 30, 2025 |
| Year Ended 31-Mar-2025 (Q4 FY25) | 23-May-2025 | Declared | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 14-Feb-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 14-Nov-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 14-Aug-2024 | Declared | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Year Ended 31-Mar-2024 (Q4 FY24) | 24-May-2024 | Declared | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 14-Feb-2024 | Declared | To consider and approve the financial results for the period ended December 31, 2023 |
| Quarter Ended 30-Sep-2023 (Q2 FY24) | 10-Nov-2023 | Declared | To consider and approve the financial results for the period ended September 30, 2023 |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about GLENMARK PHARMACEUTICALS BSE Disclosures
What is the latest BSE announcement by GLENMARK PHARMACEUTICALS?
The latest BSE disclosure by GLENMARK PHARMACEUTICALS (GLENMARK), filed on 2026-10-06T08:39:28, is: "Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release". Bsenexus tracks every official filing for GLENMARK PHARMACEUTICALS with AI-powered summaries on its announcements feed.
When is GLENMARK PHARMACEUTICALS's next board meeting?
No upcoming board meeting is currently tracked for GLENMARK PHARMACEUTICALS. Companies disclose meeting intimations under SEBI LODR, and scheduled dates appear on the Bsenexus Results Calendar.
When does GLENMARK PHARMACEUTICALS declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. GLENMARK PHARMACEUTICALS's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.